Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FOXMEYER SALES GROW 16% TO $667 MIL. IN FIRST QUARTER WITH OPERATING EARNINGS AHEAD 40% TO $10 MIL.; PHAR-MOR AGREEMENT WILL HELP FUEL FUTURE GROWTH

Executive Summary

National Intergroup's FoxMeyer wholesale drug subsidiary posted a 16% sales gain to $667 mil. in the first quarter of fiscal 1991. For the three months ended June 30, National Intergroup reported that FoxMeyer generated operating earnings (before goodwill) of $10 mil., up 39% from the same period last year. "The results of the quarter reflect strong independent and institutional sales, along with significant increases in chain store sales from existing and newly added accounts," FoxMeyer President and CEO Robert King said. "At the same time progress continues to be made in reducing costs while maintaining and improving customer service levels." A five-year, $2.8 bil. supply agreement with the drug chain Phar-Mor was announced by National Intergroup management at the company's annual shareholders meeting July 25. The company also said it has picked up additional business from K-mart, which is consolidating its wholesale accounts. FoxMeyer is currently the subject of a tug-of-war between National Intergroup management, which plans to divest all of the diversified companies holdings except FoxMeyer, and a dissident shareholder group, Centaur Partners, which wants to liquidate the entire company, including the wholesale drug business.
UsernamePublicRestriction

Register

PS017850

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel